LED Medical Signs Agreement with BC Cancer Agency to Create Oral Cancer Test



BURNABY, British Columbia – January 14, 2014 – LED Medical Diagnostics is proud to announce that it has signed an agreement with the BC Cancer Agency to form a collaborative relationship with Genome British Columbia (Genome BC) to create and commercialize a progression-risk assessment test for oral cancer. The test, the first of its kind for oral cancer, is based on a quantifiable genetic phenomenon known as “Loss of Heterozygosity,” or “LOH.”

“I am very excited to work with Genome BC and the BC Cancer Agency on a technology that could help clinicians distinguish between high-risk and low-risk oral pre-cancers,” said LED’s founder and director, Peter Whitehead. “Until recently, a major barrier to oral cancer prevention has been the lack of validated risk predictors for oral premalignant lesions. In other words, there has been no way, until now, to know whether or not an oral lesion is likely to convert into cancer. This test, which measures specific genetic changes that have been shown to predict aggressive tumour growth, has the potential to lower oral cancer morbidity and mortality rates.”

Oral cancer’s reputation as a killer is based on statistical reality: the disease is commonly detected late, when the necessary interventions are profound, and the prognosis pessimistic. “Throughout the development process,” said Whitehead, “we will strive to create the first test that quantifies the likelihood that an oral lesion will progress to cancer. Its modality as a minimally invasive, in-office procedure potentially means that high-risk lesions can be diagnosed earlier. The clinician, in turn, can fast-track patients who test positive for LOH onto the appropriate disease-management pathway, which will mean less invasive, less costly treatments, and more optimistic long-term prognoses. On the other hand, patients with lesions that test negative for LOH can be spared the psychological and physical trauma of unnecessary and costly interventions.”

The project, titled “Development of an actionable molecular test for risk assessment of oral precancers,” is funded by the Genome BC Strategic Opportunities Fund, and is designed to leverage research funded by the National Institute of Health and the Terry Fox Research Institute. Dr. Catherine Poh, project Team Leader, is an Associate Professor, Faculty of Dentistry, University of British Columbia, and a Senior Clinician Scientist of the British Columbia Oral Cancer Prevention Program at the BC Cancer Agency.

Oral Cancer Background

Over the past few decades, North America has seen a general improvement in cancer treatment outcomes, thanks to screening programs, new treatment options, and a general decline in tobacco use. The improvement in oral cancer incidence and mortality statistics has been less dramatic, however, than for cancers such as cervical, colon and prostate cancer, for which established screening programs exist.

According to the SEER database, when discovered in early stages, oral cancer’s 5-year survival rate is ~83%. Unfortunately, oral cancer is typically discovered in its later stages, when the 5-year survival rate is around ~ 36%. Clearly, early detection is critical for survival – oral cancer’s high mortality rate is directly related to the lack of early detection of potentially malignant lesions. The creation of a commercially available risk-assessment test for oral cancer has significant implications for the amelioration of these statistics.

About the BC Cancer Agency

The BC Cancer Agency is part of the Provincial Health Services Authority (PHSA), providing province-wide specialty healthcare. Together, we are transforming healthcare through innovation. The BC Cancer Agency provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. For more information, visit www.bccancer.ca.

About Genome British Columbia

Genome British Columbia is a catalyst for the life sciences cluster on Canada’s West Coast, and manages a cumulative portfolio of over $625M in research projects and science and technology platforms. Working with governments, academia and industry across sectors such as forestry, fisheries, agriculture, environment, bioenergy, mining and human health, the goal of the organization is to generate social and economic benefits for British Columbia and Canada. For more information, visit www.genomebc.ca.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol “LMD”, the OTCQX under the symbol “LEDIF”, as well as the Frankfurt Stock Exchange under the symbol “LME”. For more information, visit www.ledmd.com.

Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope® Vx systems sold globally and they have been used to perform more than 25 million exams. For more information, call 604.434.4614 or visit www.leddental.com.